ABT vs EW vs PFE Stock Comparison

Abbott Laboratories, Edwards Lifesciences and Pfizer Prices as of Nov 13, 2026 Peers: Industry group
ABT Abbott Laboratories
$108.54 +5.4% 1M -16.0% 1Y
Market cap
$189.59B
P/E
40.3x
Revenue (TTM)
$48.23B
Div. yield
0.02%
Medical Devices Healthcare
2 wins
EW Edwards Lifesciences Corp
$107.18 +24.0% 1M +24.5% 1Y
Market cap
$62.08B
P/E
61.2x
Revenue (TTM)
$6.67B
Div. yield
–
Medical Devices Healthcare
6 wins
PFE Pfizer Inc
$28.90 -1.1% 1M +12.1% 1Y
Market cap
$166.13B
P/E
41.2x
Revenue (TTM)
$63.63B
Div. yield
0.06%
Pharmaceuticals Healthcare
4 wins

Head to Head

12 decided of 12

Edwards Lifesciences leads on 6 of the 12 questions below (Edwards Lifesciences 6, Pfizer 4, Abbott Laboratories 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionABTEWPFELeader
Larger companyMarket capitalisation $189.59B $62.08B $166.13B ABT
Cheaper on earningsLower P/E, profitable companies only 40.3x 61.2x 41.2x ABT
Cheaper on forward earningsLower price / next fiscal year consensus EPS 19.1x 37.6x 9.8x PFE
Faster revenue growthRevenue growth, trailing twelve months +10.0% +13.4% +1.3% EW
More profitableNet margin, trailing twelve months 9.7% 15.2% 6.3% EW
Better return on capitalReturn on invested capital 5.7% 8.7% 12.3% PFE
Less leveragedLower net debt / EBITDA 2.5x -2.5x 1.9x EW
Higher dividend yieldTrailing dividend yield 0.02% 0.00% 0.06% PFE
Better 1-year returnPrice return, last 12 months -16.0% +24.5% +12.1% EW
Better 5-year returnAnnualised price return, 5 years -3.3%/yr -1.6%/yr -10.3%/yr EW
Less volatileAnnualised volatility, 1 year 28.5% 25.5% 21.7% PFE
Higher overall scoreMean of the five percentile scores vs peers 56/100 77/100 68/100 EW

Percentile Scorecard

ABTEWPFE

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisABTEWPFE
Valuation 74 #65 of 243 61 #96 of 243 95 #37 of 660
Growth 26 #168 of 228 57 #99 of 228 37 #392 of 619
Profitability 82 #41 of 222 96 #10 of 222 92 #50 of 595
Financial Health 33 #167 of 248 87 #34 of 248 25 #516 of 683
Shareholder Returns 65 #56 of 158 84 #26 of 158 91 #44 of 459
Overall 56 77 68
  • ABT ranked among 252 companies in Medical Devices and Diagnostics
  • EW ranked among 252 companies in Medical Devices and Diagnostics
  • PFE ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodABTEWPFESPY
1 month +5.4%+24.0%-1.1% -2.0%
3 months -2.4%+17.0%+7.9% -2.8%
6 months +28.5%+31.7%+14.1% +2.0%
Year to date -13.4%+25.7%+16.1% +10.6%
1 year -16.0%+24.5%+12.1% +12.2%
3 years +11.8%+62.9%-1.2% +68.1%
3 years, per year +3.8%+17.7%-0.4% +18.9%
5 years -15.5%-7.6%-41.9% +61.4%
5 years, per year -3.3%-1.6%-10.3% +10.1%
10 years +170.4%+253.3%-11.3% +248.5%
10 years, per year +10.5%+13.5%-1.2% +13.3%

Risk

MeasureABTEWPFESPY
Volatility, 1Y 28.5%25.5%21.7% 13.6%
Downside volatility, 1Y 27.8%24.7%21.9% 13.9%
Beta vs S&P 500, 1Y 0.070.580.26 1.00
Return / volatility, 1Y -0.560.960.56 0.90
Max drawdown, 5Y -41.6%-54.3%-64.8% -25.4%
From 52-week high -16.9%0.0%-6.1% -3.2%
52-week high $130.59$107.18$30.79 $779.14
52-week low $82.56$75.87$23.67 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleABTEWPFE
P/E now vs peer median 40.0xmedian 26.5x 60.9xmedian 26.5x 40.8xmedian 17.0x
P/S now vs peer median 3.9xmedian 2.7x 9.2xmedian 2.7x 2.6xmedian 8.4x
EV/EBITDA now vs peer median 20.3xmedian 18.4x 35.8xmedian 18.4x 8.2xmedian 14.6x
P/FCF now vs peer median 27.8xmedian 25.4x 43.3xmedian 25.4x 14.0xmedian 19.0x
P/B now vs peer median 3.6xmedian 2.5x 5.6xmedian 2.5x 1.8xmedian 2.0x
PEG now vs peer median -13.92median 0.98 -6.65median 0.98 -1.47median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsABTEWPFE
Revenue $48.23B $6.67B $63.63B
Gross profit $27.46B $5.21B $46.69B
Operating income $6.65B $1.44B $19.40B
Net income $4.70B $1.02B $4.06B
Free cash flow $6.76B $1.42B $11.79B
R&D $3.31B $1.09B $11.52B
EPS (diluted) $2.70 $1.76 $0.70
Cash & equivalents $4.05B $3.11B $1.82B
Total debt $31.16B $598.80M $62.67B
Shares (diluted) 1.74B 577.60M 5.75B
Enterprise value $163.46B $45.29B $113.48B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricABTEWPFE
P/E 40.0x 60.9x 40.8x
P/FCF 27.8x 43.3x 14.0x
P/Operating cash flow 21.2x 35.9x 11.6x
P/S 3.9x 9.2x 2.6x
P/B 3.6x 5.6x 1.8x
P/Tangible book 5.9x 6.3x 3.8x
EV/EBITDA 20.3x 35.8x 8.2x
EV/EBIT 32.3x 40.0x 11.0x
EV/Revenue 4.5x 8.6x 3.3x
EV/FCF 31.8x 40.5x 18.1x
EV/Operating cash flow 24.3x 33.6x 15.0x
PEG (3Y EPS CAGR) -13.92 -6.65 -1.47

Growth

14 metrics
MetricABTEWPFE
Revenue growth (1Y) 10.0% 13.4% 1.3%
Revenue CAGR (3Y) 6.5% 16.9% -3.2%
Gross profit growth (1Y) 12.1% 13.2% 1.3%
Gross profit CAGR (3Y) 7.8% 13.7% 2.7%
Operating income growth (1Y) -13.8% 1.1% -4.3%
Operating income CAGR (3Y) 3.5% 5.8% 7.4%
Net income growth (1Y) -66.4% -25.2% -58.9%
Net income CAGR (3Y) -3.1% -10.6% -27.2%
EPS growth (1Y) -66.1% -24.5% -59.2%
EPS CAGR (3Y) -2.9% -9.2% -27.7%
Operating cash flow growth (1Y) -2.9% 68.9% 8.4%
Operating cash flow CAGR (3Y) 10.6% 18.1% 5.6%
Free cash flow growth (1Y) -2.3% 77.1% 13.6%
Free cash flow CAGR (3Y) 14.6% 20.8% 13.0%

Profitability

14 metrics
MetricABTEWPFE
Gross margin 56.9% 78.0% 73.4%
EBITDA margin 21.9% 24.2% 40.7%
Operating margin 13.8% 21.6% 30.5%
Pretax margin 13.6% 21.5% 6.7%
Net margin 9.7% 15.2% 6.3%
FCF margin 14.0% 21.3% 18.5%
Operating cash flow margin 18.4% 25.7% 22.3%
Return on equity 9.1% 9.4% 4.7%
Return on assets 4.3% 7.2% 2.0%
Return on invested capital 5.7% 8.7% 12.3%
Return on capital employed 7.2% 11.6% 11.3%
Asset turnover 0.4x 0.5x 0.3x
Cash conversion (OCF / net income) 1.9x 1.7x 3.5x
Stock comp / revenue 1.5% 2.6% 1.7%

Financial Health

11 metrics
MetricABTEWPFE
Debt / assets 28.8% 4.2% 30.6%
Debt / equity 0.6x 0.1x 0.7x
Net debt / EBITDA 2.5x -2.5x 1.9x
Debt / FCF 4.6x 0.4x 5.3x
Liabilities / assets 52.3% 22.5% 56.4%
Equity / assets 47.7% 77.5% 43.6%
Interest coverage 6.7x – –
Current ratio 1.5x 4.6x 1.4x
Quick ratio 0.8x 3.5x 0.9x
Cash ratio 0.3x 2.9x 0.4x
Altman Z-score 3.36 14.42 2.34

Shareholder Returns

7 metrics
MetricABTEWPFE
Dividend yield 2.3% – 6.0%
Net buyback yield 0.7% 0.9% –
Shareholder yield 3.0% 0.9% 6.0%
Payout ratio (earnings) 92.0% – 241.2%
Payout ratio (FCF) 64.0% – 83.1%
Dividend growth (1Y) 6.9% – 0.9%
Dividend CAGR (3Y) 7.4% – 2.2%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusABTEWPFE
Forward P/E 19.1xFY2026 37.6xFY2026 9.8xFY2026
EPS, next fiscal year $5.69FY2026 $2.85FY2026 $2.95FY2026
EPS growth, next FY +10.5%FY2026 +11.3%FY2026 -8.4%FY2026
EPS growth, the year after +10.2% +12.6% -5.8%
Revenue, next fiscal year $52.99BFY2026 $7.28BFY2026 $61.46BFY2026
Revenue growth, next FY +19.5%FY2026 +19.9%FY2026 -1.8%FY2026
Revenue growth, the year after -2.3% -2.2% +4.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersABTEWPFE
Held by institutions 79.2% 90.6% 66.9%
Institutions holding 2,983 1,326 2,842
Change in shares held, QoQ +0.3% +20.4% +2.0%
Institutions buying 1,261 641 1,327
Institutions selling 1,379 456 1,206
Buyers to sellers 0.91 1.41 1.10

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ABTEWPFE
ABT 1.00 0.32 0.27
EW 0.32 1.00 0.18
PFE 0.27 0.18 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ABT, EW and PFE?

Abbott Laboratories (ABT) is the largest by market capitalisation: Abbott Laboratories (ABT) $189.59B, Edwards Lifesciences (EW) $62.08B, Pfizer (PFE) $166.13B.

Which stock is cheaper, ABT, EW and PFE?

Abbott Laboratories (ABT) trades on the lowest price-to-earnings ratio (Abbott Laboratories (ABT) 40.3x, Edwards Lifesciences (EW) 61.2x, Pfizer (PFE) 41.2x). On next year's consensus earnings, Pfizer (PFE) is cheapest (Abbott Laboratories (ABT) 19.1x, Edwards Lifesciences (EW) 37.6x, Pfizer (PFE) 9.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Edwards Lifesciences (EW) grew revenue fastest over the trailing twelve months: Abbott Laboratories (ABT) +10.0%, Edwards Lifesciences (EW) +13.4%, Pfizer (PFE) +1.3%.

Which company is more profitable?

Edwards Lifesciences (EW) has the highest net margin (Abbott Laboratories (ABT) 9.7%, Edwards Lifesciences (EW) 15.2%, Pfizer (PFE) 6.3%). On return on invested capital, Pfizer (PFE) leads (Abbott Laboratories (ABT) 5.7%, Edwards Lifesciences (EW) 8.7%, Pfizer (PFE) 12.3%).

Which stock has performed better?

Over the past year Edwards Lifesciences (EW) returned the most: Abbott Laboratories (ABT) -16.0%, Edwards Lifesciences (EW) +24.5%, Pfizer (PFE) +12.1%. Over five years, Edwards Lifesciences (EW) compounded fastest (Abbott Laboratories (ABT) -3.3%/yr, Edwards Lifesciences (EW) -1.6%/yr, Pfizer (PFE) -10.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Pfizer (PFE) has the highest dividend yield: Abbott Laboratories (ABT) 0.02%, Edwards Lifesciences (EW) 0.00%, Pfizer (PFE) 0.06%. Edwards Lifesciences (EW) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Pfizer (PFE) has been the steadiest (Abbott Laboratories (ABT) 28.5%, Edwards Lifesciences (EW) 25.5%, Pfizer (PFE) 21.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ABT, EW and PFE?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Edwards Lifesciences (EW) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.